Braveheart Bio (NASDAQ:BRVE) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Braveheart Bio (NASDAQ:BRVE) in a report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $45.00 price target on the stock.

Several other equities research analysts also recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Braveheart Bio in a research note on Monday. They issued a “buy” rating and a $48.00 price objective on the stock. Cantor Fitzgerald assumed coverage on shares of Braveheart Bio in a research note on Monday. They set an “overweight” rating and a $40.00 target price for the company. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 price target for the company. TD Cowen assumed coverage on shares of Braveheart Bio in a research report on Monday. They issued a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $45.25.

Braveheart Bio Price Performance

Shares of BRVE stock opened at $26.95 on Monday. Braveheart Bio has a 12 month low of $24.31 and a 12 month high of $32.00.

Insider Buying and Selling

In other news, Director David Charles Lubner acquired 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the completion of the transaction, the director owned 55,555 shares in the company, valued at approximately $999,990. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Bio Fund Iv L.P. Ah bought 1,100,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. This represents a 12.05% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 8,751,942 shares of company stock worth $157,534,956.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.